Results 131 to 140 of about 23,951 (282)

Apheresis practice variation during the COVID-19 pandemic: Results of a survey

Background: The COVID-19 pandemic affected healthcare delivery across all specialties including apheresis. To describe the changes in apheresis service practices that occurred during the pandemic, the American Society for Apheresis (ASFA) Apheresis ...
Tanhehco, Yvette C, Ibeh, Nnaemeka, Wu, Ding Wen, Noland, Daniel K, Zantek, Nicole D, Chhibber, Vishesh, Stephens, Laura D, DeChristopher, Phillip J, Wehrli, Gay, Li, Yanhua, Martin, Marisa Claudia Saint, Alsammak, Mohamed, Lu, Wen   +12 more
core   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Citrate anticoagulation: Are blood donors donating bone?

, 2015
An estimated 2.4 million volunteer apheresis blood donation procedures were performed in the United States in 2010, and increases in the proportion of transfused blood products derived from apheresis blood collections have been consistently reported ...
Walter Bialkowski, Bruhn, Roberta, Bruhn, R, Gustaf Edgren, Bialkowski, W, Edgren, Gustaf, Bialkowski, Walter, Paula Papanek, Papanek, P, Edgren, G,, Papanek, Paula E., Roberta Bruhn   +11 more
core   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, Volume 13, Issue 35, 24 June 2026.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
In this exploratory study, no statistically significant differences in effectiveness, safety, or cost were observed between EFG and LPE, nor between RACT and oral immunosuppressants for pre‐thymectomy preparation in MG. These findings are hypothesis‐generating and warrant prospective validation.
Qian Zhou, Ting He, Yuanda Cheng, Kangzhi Chen, Yuzhen Ouyang, Xiaohua Dong, Guanzhong Shi, Zeyi Wen, Huan Yang   +8 more
wiley   +1 more source

Adverse events in apheresis : an update of the WAA registry data

, 2016
Apheresis with different procedures and devices are used for a variety of indications that may have different adverse events (AEs). The aim of this study was to clarify the extent and possible reasons of various side effects based on data from a ...
Liumbruno, G, Hrdlickova, R., Mori, E., Tomaz, J.,, Dykes, Josefina,, Mörtzell Henriksson, M, Gasova, Z., Dhondt, A.,, Newman, E, Toss, F.,, Gasova, Z, Axelsson, C.G., Lanska, M., Brink, B., Aandahl, A.,, Norda, R, Brink, B.,, Berlin, G, Dykes, J.,, Mori, E, Brink, B, Ramlow, W.,, Stegmayr, B., Hrdlickova, R, Wahlström, A., Sikole, A.,, Ptak, J, Wahlström,, A.,, Prophet, H, Eloot, Sunny, Audzijoniene, J., Audzijoniene, J, Mörtzell Henriksson, Monica,, Norda, R.,, Berlin, Gösta, Berlin, Gösta,, Witt, V, Deeren, D.,, Lund University., Ramsauer, Bernd,, Prophet, H.,, Vrielink, H.,, Ramlow, W., Rock, G.,, Toss, F, Sikole, A, Derfler, K.,, Stegmayr, B, Rombout, S.,, Mazic, S.,, Berlin, G., Liumbruno, G.,, Griskevicius, A.,, Eloot, S, Dykes, Josefina, Rock, G, Lanska, M.,, Axelsson, C.G.,, Mazic, S, Mörtzell Henriksson, Monica, Rombout, S., Newman, E., Dhondt, Annemieke, Tomaz, J., Norda, R., Strineholm, V., Lalic, K., Stegmayr, B.,, Griskevicius, A., Blaha, M, Ramsauer, Bernd, Gasova, Z.,, Dykes, J., Toss, F., Aandahl, A., Hrdlickova, R.,, Mori, E.,, Axelsson, CG, Sikole, A., Deeren, D, Rock, G., Eloot, S.,, Stegmayr, Bernd,, Witt, V., Derfler, K., Mörtzell Henriksson, M.,, Blaha, M., Leitner, G, Liumbruno, G., Strineholm, V.,, Dykes, J, Dhondt, A., Leitner, G.,, Knutson, F.,, Lalic, K, Witt, V.,, Lalic, K.,, Nilsson, T., Lanska, M, Mörtzell Henriksson, M., Eloot, S., Prophet, H., Nilsson, T.,, Ptak, J.,, Rombout, S, Leitner, G., Ptak, J., Aandahl, A, Tomaz, J, Strineholm, V, Blaha, M.,, Deeren, D., Audzijoniene, J.,, Knutson, F, Nilsson, T, Mazic, S., Knutson, F., Wahlström,, A., Vrielink, H, Ramsauer, B.,, Derfler, K, Ramsauer, B., Wahlström, A, Ramlow, W, Axelsson, C G, Newman, E.,, Vrielink, H., Griskevicius, A, Dhondt, A, Ramsauer, B, Stegmayr, Bernd   +130 more
core   +1 more source

Why Pediatric CAR‐T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 32-35, July 2026.
Lisa Hanquet, Jean‐Michel Dogné, Flora T. Musuamba   +2 more
wiley   +1 more source

Extracellular Vesicles as Drivers of Lung Endothelial Dysfunction in ARDS: Mechanisms and Therapeutic Opportunities

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review summarizes how extracellular vesicles from diverse pulmonary and extrapulmonary sources contribute to endothelial dysfunction in ARDS and evaluates emerging endothelial‐targeted therapies for their potential to mitigate EV‐mediated pathogenic mechanisms.
Mohammed Yaman Al Matni, Patrick Belvitch, Steven M. Dudek, Eleftheria Letsiou   +3 more
wiley   +1 more source

Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I

, 2017
Granulocyte and monocyte apheresis has been used in different immune-mediated disorders, mainly inflammatory bowel diseases. The removal of activated leukocytes and several additional immunomodulatory mechanisms have been so far suggested to explain the ...
Negrini S., Strada P., Ubezio G., Ghio M., Contini P., Bodini G., Savarino V., Trucchi C.   +7 more
core   +1 more source